SSY Group (HK:2005) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
SSY Group Limited has announced that its diabetes medication, Trelagliptin Succinate, has received registration approval from China’s National Medical Products Administration, marking the company’s fourth approved bulk drug in the country. This long-acting inhibitor is used to treat type 2 diabetes and the update is aimed at keeping shareholders and potential investors informed of the company’s latest developments.
For further insights into HK:2005 stock, check out TipRanks’ Stock Analysis page.
